| Database ID | Agent | Target | Cancer Type | Detail |
| DB00001 | ipilimumab | Cytotoxic Tlymphocyte antigen 4 (CTLA4) | melanoma | view |
| DB00002 | pembrolizumab | The antiprogrammeddeathreceptor1 | melanoma | view |
| DB00003 | pembrolizumab | The antiprogrammeddeathreceptor1 | melanoma | view |
| DB00004 | nivolumab | PD1 | melanoma | view |
| DB00005 | nivolumab | PD1 | melanoma | view |
| DB00006 | ipilimumab | Cytotoxic Tlymphocyte antigen 4 (CTLA4) | melanoma | view |
| DB00007 | ipilimumab | Cytotoxic Tlymphocyte antigen 4 (CTLA4) | melanoma | view |
| DB00008 | Nivolumab and ipilimumab | NA | melanoma | view |
| DB00009 | ipilimumab | Cytotoxic Tlymphocyte antigen 4 (CTLA4) | melanoma | view |
| DB00010 | bevacizumab | Vascular endothelial growth factor
Epidermal growth factor receptor | colorectal cancer | view |
| DB00011 | bevacizumab | Vascular endothelial growth factor
Epidermal growth factor receptor | colorectal cancer | view |
| DB00012 | bevacizumab | Vascular endothelial growth factor
Epidermal growth factor receptor | colorectal cancer | view |
| DB00013 | bevacizumab | Vascular endothelial growth factor
Epidermal growth factor receptor | colorectal cancer | view |
| DB00014 | bevacizumab | Vascular endothelial growth factor
Epidermal growth factor receptor | colorectal cancer | view |
| DB00015 | bevacizumab | Vascular endothelial growth factor
Epidermal growth factor receptor | colorectal cancer | view |